Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TPST
TPST
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TPST News
Tempest Acquires CAR-T Assets, Expands Pipeline
Feb 04 2026
Newsfilter
Tempest Therapeutics Announces Warrant Dividend Distribution Date of January 30, 2026
Jan 20 2026
Globenewswire
Tempest Therapeutics Closes $4.25 Million Registered Direct Offering
Nov 26 2025
Newsfilter
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Nov 24 2025
NASDAQ.COM
Crude Oil Declines More Than 2%; Lowe's Stock Rises Following Q3 Earnings Report
Nov 19 2025
Benzinga
Nasdaq Rises by More Than 100 Points; Target Lowers Earnings Outlook
Nov 19 2025
Benzinga
Reasons Behind Tempest Therapeutics (TPST) Stock Plummeting 45% Today
Nov 19 2025
Benzinga
Tempest Releases Financial Results for Q3 2025 and Offers Business Update
Nov 05 2025
Newsfilter
Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor
Jun 12 2025
NASDAQ.COM
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
Jun 11 2025
Newsfilter
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Jun 09 2025
Benzinga
Tempest Therapeutics Inc. Loss At -$10.86 Mln In Q1
May 13 2025
NASDAQ.COM
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
Apr 28 2025
Newsfilter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com
Apr 21 2025
Investing.com
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Apr 21 2025
Newsfilter
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Apr 10 2025
Benzinga
Show More News
